ADC

192개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved192 programs
ADCLimited DatastaleSeagen, a wholly owned subsidia…Phase 1

sigvotatug vedotin (sigvotatug vedotin)

Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small Cell Lung

#CarcinomaNon-SmallCellLung#ADC#Phase1#antibody-drug-conjugate#Carcinoma+3
Trials 5Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

5-hydroxytryptamine subtype 3 receptor antagonist (5-hydroxytryptamine subtype 3 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 4Status Recruiting
ADCLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Patritumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 4Status Recruiting
ADCStandard DatabasestaleSeagen Inc.Phase 2

denintuzumab mafodotin (denintuzumab mafodotin)

Lymphoma, B-cell; Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-cell

#LymphomaB-cell#ADC#Phase2#antibody-drug-conjugate#Lymphoma+2
Trials 4Status Discontinued
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin, anti-PD-1 antibody.)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 3Status Recruiting
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus chidamide (Consolidation therapy- 3 or 6 cycles of BvC, Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin+Anlotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 3Status Active
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus Chidamide (Induction therapy-3 cycles of BvC, Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
ADCLimited DatastaleHenry Ford Health SystemPhase 1

sacituzumab govitecan (Trodelvy, Sacituzumab govetican)

Gastrointestinal Cancer · Gastrointestinal Cancer

#GastrointestinalCancer#ADC#Phase1#antibody-drug-conjugate#Henry
Trials 3Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, disitamab vedotin, sintilimab, capecitabine)

Rectal Cancer · Rectal Cancer

#RectalCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 3Status Recruiting
ADCLimited DatastaleRochePhase 1

trastuzumab (Herceptin, trastuzumab-MCC-DM1)

Metastatic Breast Cancer · MET

#MET#ADC#Phase1#antibody-drug-conjugate#MetastaticBreastCancer+1
Trials 3Status Active
ADCStandard DatabasestaleMacroGenicsPhase 2

vobramitamab duocarmazine (vobramitamab duocarmazine)

Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+2
Trials 3Status Discontinued
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy)

Gastric Cancer · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#GastricCancer+1
Trials 2Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Bicalutamide)

Extramammary Paget Disease; Scrotum Disease · Extramammary Paget Disease

#ExtramammaryPagetDisease#ADC#Phase2#antibody-drug-conjugate#ScrotumDisease+1
Trials 2Status Recruiting
ADCLimited DatastaleThe First Affiliated Hospital w…Preclinical

Disitamb Vedotin (Disitamb Vedotin)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#The
Trials 2Status Active
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Induction without Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#antibody-drug-conjugate#HodgkinLymphoma+2
Trials 2Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

Patritumab (Patritumab)

Head and Neck Neoplasms · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#ADC#Phase2#antibody-drug-conjugate#HeadandNeckNeoplasms+1
Trials 2Status Active
ADCLimited DatastaleGenentech, Inc.Phase 2

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

Follicular Lymphoma; Diffuse Large B-Cell Lymphoma · Follicular Lymphoma

#FollicularLymphoma#ADC#Phase2#antibody-drug-conjugate#DiffuseLargeB-CellLymphoma+1
Trials 2Status Active
ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting
ADCLimited DatastaleJiangsu HengruiPhase 2

A2: SHR-A1811 with Camrelizumab with famitinib (A2: SHR-A1811 with Camrelizumab with famitinib)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#antibody-drug-conjugate#Jiangsu
Trials 1Status Recruiting

6 / 10 pages

← PreviousNext →